Equillium is dedicated to finding new treatments to dramatically improve the lives of patients with diseases where treatment options are limited or not available. Our lead product candidate, itolizumab, has a novel mechanism that blocks key drivers of inflammation that lie at the root of many diseases.
Hematopoietic stem cell transplant (HSCT) provides a potentially curative option for some types of cancer, but it comes with the risk of GVHD. GVHD occurs when the transplanted immune system attacks the recipient’s body and is the leading cause of non-cancer death in stem cell transplant recipients.
Lupus nephritis is among the most serious complications of systemic lupus erythematosus (SLE), occurring in 30 – 60% of individuals with SLE. In lupus nephritis, the body’s own immune system attacks the kidneys, causing inflammation and significantly reducing kidney function over time.
Individuals with asthma live with constant airway inflammation. Certain environmental triggers, exercise or illness can cause even more swelling and constriction of the muscles around the airway, making it difficult to breath.
A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Itolizumab (EQ001) in Subjects With Moderate to Severe Uncontrolled Asthma